IBL Healthcare Limited
PPSX:IBLHL40.16
PKR
-1.07
(-2.60%)
ISIN
PK0095501018
Return %
Stock
S&P 500
1Y
-20.94
14.20
3Y
49.03
81.12
5Y
-26.24
68.34
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.Company Description
- CEO
- Sheraz Khan
- Full Time Employees
- 208
- Sector
- Distribution services
- Industry
- Medical distributors
- Address
- Karachi Pakistan
- IPO Date
- Mar 31, 2009
- Website
- iblhc.com
- Similar Companies
- Business
- IBL Healthcare Limited is a Pakistan-based healthcare, nutrition, and medical supplies company engaged in the marketing, sales, supply chain management, and distribution of consumer health products, infant and clinical nutrition, and medical devices. Founded in 1997 as a private limited company and converted into a public limited company in 2009, the company is headquartered in Karachi, Pakistan, and operates as a subsidiary of The Searle Company Limited within the International Brands Limited Group. The company's core product and service portfolio comprises Nutritional Products, including infant and growing-up formulas, pediatric nutrition, and specialized clinical nutrition marketed under licensing partnerships with global brand owners such as Mead Johnson Nutrition (including Enfamil and Enfagrow) and Nestlé Health Science; Medical Devices and Disposables, including renal care products (hollow fiber dialyzers, hemodialysis blood tubing lines, and arteriovenous fistula needles), critical care and anesthesia supplies (breathing circuits, anesthesia masks, bacterial filters, suction catheters, and oxygen therapy consumables), and general hospital disposables (intravenous infusion sets, blood transfusion bags, surgical blades, and examination gloves); Consumer Health and Wellness Solutions, including dietary supplements, Stevia-based natural sweeteners, vision care products, and over-the-counter remedies; and Commercial Services, encompassing marketing management, brand development, regulatory affairs, and nationwide warehousing and cold-chain distribution executed through associated logistics affiliate IBL Operations (Private) Limited. In recent operational developments, IBL Healthcare Limited has executed a strategic realignment focusing on high-margin health, wellness, and specialized medical device segments while rationalizing and divesting traditional pharmaceutical and ophthalmology lines. To mitigate foreign exchange volatility and import cost pressures, the company has expanded its product localization initiative, transitioning selected product lines to local toll manufacturing arrangements utilizing The Searle Company Limited's manufacturing facilities. Additionally, the company has expanded its premium pediatric nutrition offerings with the launch and market repositioning of advanced formula lines such as the Enfa A+ NeuroPro series, broadened its domestic institutional footprint across hospitals and dialysis centers, and optimized its nationwide distribution network to support high-growth wellness and adult clinical nutrition categories.